Could a sticky patch on your chest predict heart failure relapse?

NCT ID NCT07699874

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This pilot study investigates whether a continuous remote ECG monitor, worn as a chest patch, can predict hospital readmission or death within 30 days after discharge in patients with heart failure and atrial fibrillation. Fifty participants will wear the Vivalink ECG patch at home, which streams real-time heart data to healthcare providers. The goal is to see if early warning signs can be detected before a patient's condition worsens, potentially improving follow-up care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vivalink multi-vital wearable ECG monitor (chest-worn biosensor patch)
What this could lead to
If successful, this approach could help doctors identify patients at high risk of readmission early, potentially reducing hospital returns and improving care after discharge.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to all patients. The device may be uncomfortable or fail to detect all relevant events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fattouma Bourguiba University Hospital

    Monastir, 5000, Tunisia

More trials for these conditions

Other studies related to the condition(s) this trial covers.